Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mometasone/formoterol - Merck & Co / Novartis

Drug Profile

Mometasone/formoterol - Merck & Co / Novartis

Alternative Names: Dulera; Formoterol/mometasone; MF/F; MFF 258; MK-0887A; MK-08887A; MK-887A; Mometasone furoate/formoterol fumarate; SCH 418131; Zenhale

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; Schering-Plough
  • Developer Merck & Co; Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • No development reported Allergic asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Dec 2017 Merck Sharp & Dohme completes a phase III trial in Asthma (In children) in Latvia, Hungary, Denmark, Guatemala, Mexico, Romania, South Africa and USA (Inhalation) (NCT02741271) (EudraCT 2009-010110-30)
  • 15 Mar 2016 Phase-III clinical trials in Asthma (In children) in Latvia and Hungary (Inhalation) (EudraCT2009-010110-30)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top